15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Brain‐resident memory CD8 + T cells induced by congenital CMV infection prevent brain pathology and virus reactivation

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p id="P5">Congenital HCMV infection is a leading infectious cause of long-term neurodevelopmental sequelae. Infection of newborn mice with MCMV intraperitoneally is a well-established model of congenital HCMV infection, which best recapitulates the hematogenous route of virus spread to brain and subsequent pathology. Here we used this model to investigate the role, dynamics and phenotype of CD8 <sup>+</sup> T cells in brain following infection of newborn mice. We show that CD8 <sup>+</sup> T cells infiltrate the brain and form a pool of tissue-resident memory T cells (T <sub>RM</sub> cells) that persist for lifetime. Adoptively transferred virus-specific CD8 <sup>+</sup> T cells provide protection against primary MCMV infection in newborn mice, reduce brain pathology and remain in the brain as T <sub>RM</sub> cells. Brain CD8 <sup>+</sup> T <sub>RM</sub> cells were long-lived, slowly proliferating cells able to respond to local challenge infection. Importantly, brain CD8 <sup>+</sup> T <sub>RM</sub> cells controlled latent MCMV and their depletion resulted in virus reactivation and enhanced inflammation in brain. </p>

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          The immune modulator FTY720 targets sphingosine 1-phosphate receptors.

          Immunosuppressant drugs such as cyclosporin have allowed widespread organ transplantation, but their utility remains limited by toxicities, and they are ineffective in chronic management of autoimmune diseases such as multiple sclerosis. In contrast, the immune modulating drug FTY720 is efficacious in a variety of transplant and autoimmune models without inducing a generalized immunosuppressed state and is effective in human kidney transplantation. FTY720 elicits a lymphopenia resulting from a reversible redistribution of lymphocytes from circulation to secondary lymphoid tissues by unknown mechanisms. Using FTY720 and several analogs, we show now that FTY720 is phosphorylated by sphingosine kinase; the phosphorylated compound is a potent agonist at four sphingosine 1-phosphate receptors and represents the therapeutic principle in a rodent model of multiple sclerosis. Our results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Translating developmental time across mammalian species

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              BrdU immunohistochemistry for studying adult neurogenesis: paradigms, pitfalls, limitations, and validation.

              Bromodeoxyuridine (BrdU) is a thymidine analog that incorporates DNA of dividing cells during the S-phase of the cell cycle. As such, BrdU is used for birth dating and monitoring cell proliferation. BrdU immunohistochemistry has been instrumental for the study of the development of the nervous system, and to confirm that neurogenesis occurs in the adult mammalian brain, including in human. However, the use of BrdU for studying neurogenesis is not without pitfalls and limitations. BrdU is a toxic and mutagenic substance. It triggers cell death, the formation of teratomas, alters DNA stability, lengthens the cell cycle, and has mitogenic, transcriptional and translational effects on cells that incorporate it. All of which have profound consequences on neurogenesis. BrdU is not a marker of the S-phase of the cell cycle. As a thymidine analog, it is a marker of DNA synthesis. Therefore, studying neurogenesis with BrdU requires distinguishing cell proliferation and neurogenesis from other events involving DNA synthesis, like DNA repair, abortive cell cycle reentry and gene duplication. BrdU labeling is currently the most used technique for studying adult neurogenesis in situ. However in many instances, appropriate controls have been overlooked and events reported as the generation of new neuronal cells in the adult brain misinterpreted, which makes BrdU labeling one of the most misused techniques in neuroscience.
                Bookmark

                Author and article information

                Journal
                European Journal of Immunology
                Eur. J. Immunol.
                Wiley
                0014-2980
                1521-4141
                June 12 2018
                June 2018
                March 23 2018
                June 2018
                : 48
                : 6
                : 950-964
                Affiliations
                [1 ]Department of Histology and EmbryologyFaculty of MedicineUniversity of Rijeka Rijeka Croatia
                [2 ]Center for ProteomicsFaculty of MedicineUniversity of Rijeka Rijeka Croatia
                [3 ]Faculty of MedicineUniversity of Mostar Mostar Bosnia and Herzegovina
                [4 ]Centre for Immune RegulationDepartment of ImmunologyUniversity of Oslo Norway
                [5 ]Institute of Microbiology ETH Zürich Zürich Switzerland
                [6 ]Department of MicrobiologyUniversity of Alabama at Birmingham Birmingham Alabama USA
                Article
                10.1002/eji.201847526
                6422351
                29500823
                1d8a1148-c4f1-4bdd-a981-37697f90c6f9
                © 2018

                http://onlinelibrary.wiley.com/termsAndConditions#vor

                http://doi.wiley.com/10.1002/tdm_license_1.1

                History

                Comments

                Comment on this article